ArticleFrontiers in pharmacology2022
Access to Insulin Products in Pakistan: A National Scale Cross-Sectional Survey on Prices, Availability, and Affordability.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Sociodemographic Factors Influencing Knowledge, Attitudes, Practices, Glycaemic Control and Sight-Threatening Retinopathy Among Diabetes Patients in Rawalpindi, Pakistan: A Hospital-Based Cross-Sectional Study.Public health challenges · 2026Article
- Article
- Availability, prices, and affordability of essential medicines for cardiovascular diseases and diabetes: a multi-regional survey using the WHO/HAI methodology in Pakistan.BMC health services research · 2026Article
- Antidiabetic prescribing patterns, quality, and economic influence in resource-limited settings: evidence from a Pakistani tertiary care hospital using WHO/INRUD indicators.BMC health services research · 2026Article
- From medicine price control to deregulation: assessing policy effects on insulin access in Pakistan's private pharmacies.PloS one · 2026Article
- Pakistan's first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies.Frontiers in pharmacology · 2025Article
- Trends in global glucose lowering medication consumption: Insights from pharmaceutical sales data (2010-2021).PLOS global public health · 2025Article
- Article
- The protective role of oily fish intake against type 2 diabetes: insights from a genetic correlation and Mendelian randomization study.Frontiers in nutrition · 2024Article
- Serum uric acid and risk of diabetic neuropathy: a genetic correlation and mendelian randomization study.Frontiers in endocrinology · 2023Article
- Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and LantusFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.